FDA Should Cite Regulatory Imperative When Narrowing 510(k) Claims – Cook
This article was originally published in The Gray Sheet
FDA should consult with a three-person "supervisory" panel in deciding whether to narrow a proposed indication statement for 510(k) devices, Cook Group, Inc. suggests in March 4 comments to HHS Secretary Thompson's regulatory reform advisory committee
You may also be interested in...
The Center for Devices and Radiological Health is addressing industry concerns over FDA's handling of increasing numbers of investigational device exemption supplements and use of the agency's five-day notice program for clinical trial changes
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.